FDA Again Delays Approval Of Pfizer-BMS Anti-Clotting Drug
The drugmakers said the FDA has asked them to provide additional information on data management and verification on one of two clinical studies conducted on Eliquis, an anti-clotting drug Pfizer and Bristol-Myers have been developing together since 2007 for patients with an irregular heartbeat.
The companies said...
Already a subscriber? Click here to login